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Abstract
Objectives—This study sought to determine an aggregate, pathway-specific risk score for
enhanced prediction of death and myocardial infarction (MI).
Background—Activation of inflammatory, coagulation, and cellular stress pathways contribute
to atherosclerotic plaque rupture. We hypothesized that an aggregate risk score comprised of
biomarkers involved in these different pathways—high-sensitivity C-reactive protein (CRP), fibrin
degradation products (FDP), and heat shock protein 70 (HSP70) levels—would be a powerful
predictor of death and MI.
Methods—Serum levels of CRP, FDP, and HSP70 were measured in 3,415 consecutive patients
with suspected or confirmed coronary artery disease (CAD) undergoing cardiac catheterization.
Survival analyses were performed with models adjusted for established risk factors.
Results—Median follow-up was 2.3 years. Hazard ratios (HRs) for all-cause death and MI based
on cutpoints were as follows: CRP ≥3.0 mg/l, HR: 1.61; HSP70 >0.625 ng/ml, HR; 2.26; and FDP
≥1.0 μg/ml, HR: 1.62 (p < 0.0001 for all). An aggregate biomarker score between 0 and 3 was
calculated based on these cutpoints. Compared with the group with a 0 score, HRs for all-cause
death and MI were 1.83, 3.46, and 4.99 for those with scores of 1, 2, and 3, respectively (p for
each: <0.001). Annual event rates were 16.3% for the 4.2% of patients with a score of 3 compared
with 2.4% in 36.4% of patients with a score of 0. The C statistic and net reclassification improved
(p < 0.0001) with the addition of the biomarker score.
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Conclusions—An aggregate score based on serum levels of CRP, FDP, and HSP70 is a
predictor of future risk of death and MI in patients with suspected or known CAD.
Keywords
biomarker; C-reactive protein; fibrin degradation product; heat shock protein; myocardial
infarction
Stable coronary artery disease (CAD) can lead to severe ischemic symptoms from stenosis-
related coronary blood flow reduction, but plaque rupture leading to myocardial infarction
(MI) and death is its most devastating complication. Although many patients with CAD
never experience clinical plaque rupture, others may experience an early MI. Importantly,
distinct genetic differences distinguish patients with stable CAD versus those who
experience plaque rupture (1). Thus, signaling pathways predisposing to atherosclerosis
probably differ from those contributing to plaque vulnerability. This distinction is likely to
be crucial when considering strategies for identifying patients at risk of MI and death from
plaque rupture.
The Framingham Risk Score and similar scores are widely used to assess absolute risk of
adverse cardiac events in patients without known CAD (2,3); however, they do not reliably
predict risk of plaque rupture (and consequent MI and/or death) in patients with already
established CAD (4,5). Other biomarkers appear to predict such risk, but their associated
hazard ratios (HRs) have been modest (6–8). Our purpose is to develop a robust,
noninvasive, and simple biomarker strategy to identify CAD patients at increased risk of
plaque rupture.
The strategy we explored derived from the concept that activation of multiple pathways,
including inflammatory, stress-related, and coagulation pathways, each contribute to
coronary plaque instability. Elevated levels of high-sensitivity C-reactive protein (CRP)
reflect vascular inflammation and are associated with greater risk for subsequent
cardiovascular disease (CVD) events, but the effects are modest (9,10). Heat shock proteins
(HSPs), including HSP70, are highly conserved intracellular proteins that increase in
response to stress, and may provide evidence of increased cellular stress, and thus, a
predisposition to plaque rupture (11–13). Both fibrinogen and fibrin degradation products
(FDP), end products in the coagulation cascade, have been associated with CAD
development and severity (14,15). Moreover, D-dimer, a degradation product of fibrinogen
and soluble fibrin monomers, has been associated with adverse cardiac events (16,17). We
hypothesized that risk assessment would be markedly enhanced when the 3 biomarkers—
CRP reflecting inflammation; HSP70, associated with increased cellular stress; and FDP,
associated with coagulation cascade activation—are used in aggregate, that is, the risk of
plaque rupture would be greater when biomarkers reflected activation of 2 or 3 pathways
compared with activation of 0 or 1 pathways.
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Methods
Study population
Study participants were recruited as part of the Emory Cardiology Biobank (EMCAB),
consisting of 3,763 consecutive patients enrolled before undergoing elective or emergent
coronary angiograms across 3 Emory healthcare sites, between 2003 and 2009 (details in the
Online Appendix).
Outcomes and follow-up
Record of death was obtained from the Social Security Death Index, and the cause of death
adjudicated from medical records or direct contact was made with the patient’s family
member(s). Cardiac death was defined as death attributable to a cardiovascular cause or
sudden death due to an unknown cause. Follow-up was conducted between 1 and 5 years to
identify cases of MI and revascularization (defined as percutaneous coronary interventions
or coronary artery bypass graft [CABG] surgery). MI and revascularization occurring within
a month of enrollment were not included.
Identification of CAD and severity scoring
All coronary angiograms were scored for luminal narrowing using a modified American
Heart Association/American College of Cardiology classification of the coronaries (18).
Patients were designated as having either angiographically smooth normal coronary arteries,
nonsignificant CAD (visible plaque resulting in <50% luminal stenosis), or significant CAD
(at least 1 major epicardial vessel with ≥50% stenosis). Quantitative angiographic scoring
was performed using the Gensini score, which quantifies CAD severity by a nonlinear points
system for degree of luminal narrowing. The score has prognostic significance (19).
Sample collection
Fasting arterial blood samples for serum were drawn at cardiac catheterization and stored at
−80°C (mean 4.9 years) before analysis by FirstMark, Inc. (San Diego, California) (Online
Appendix). CRP and FDP levels were determined using a sandwich immunoassay. FDP
components included fragments D and E, D-dimer, and additional intermediate cleavage
products. HSP70 was measured with a sandwich enzyme-linked immunosorbent assay
(R&D Systems, Minneapolis, Minnesota) and optimized by FirstMark. Minimum detectable
CRP, FDP, and HSP70 concentrations were 0.1 mg/l, 0.06 μg/ml, and 0.625 ng/ml,
respectively.
Statistical analyses
Continuous variables are presented as mean ± SD, and categorical variables are presented as
proportions (percentages). Student t test, 1-way analysis of variance, and Cochran-Mantel-
Haenszel chi-square test were used as appropriate. Mann-Whitney U or Kruskall-Wallis
nonparametric tests were performed on non-normally distributed variables. The relationship
between biomarkers and outcomes was determined using the Cox proportional hazards
regression in unadjusted models and in models adjusted for established risk factors that
included clinically relevant covariates for CVD outcomes (age at baseline, race, diagnosis of
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hypertension, diabetes, dyslipidemia, use of statins, aspirin, clopidogrel, history of MI, acute
MI at presentation, estimated glomerular filtration rate [eGFR; calculated using the
Modification of Diet in Renal Disease equation], Gensini score, body mass index, left
ventricular ejection fraction [LVEF], history of CABG, and smoking status). The
proportional hazards assumption for Cox models was evaluated by plots of Schoenfeld
residuals and formal testing (a chi-square test calculated as the sum of Schoenfeld residuals).
No significant violations of the assumption were found.
Biomarkers were evaluated both as continuous (natural log transformed) per SD (Online Fig.
1) and as categorical variables based on cutpoints. Penalized B-splines within the Cox
models were also used to assess the functional form of the association between each
biomarker and events (20). We also took into consideration clinically relevant cutpoints
(21). Through these evaluations, cutpoints were determined as 3 mg/l for CRP, 1.0 μg/ml for
FDP, and 0.625 ng/ml for HSP70. The FDP cutpoint corresponded to the fourth quartile.
Analyses were performed on all participants, and in subsets of those with and those without
significant CAD.
The ability of the standard clinical model for predicting adverse events was calculated using
the C statistic from Cox regression models before and after addition of the independently
predictive biomarkers identified both individually and in aggregate (22). Using multivariate
Cox models with the previously noted clinical covariates, continuous net reclassification
improvement (NRI) and integrated discrimination improvement (IDI) metrics were
calculated. Values of p < 0.05 from 2-sided tests were considered to indicate statistical
significance. Further statistical methods are in the Online Appendix.
Results
Baseline characteristics of the 3,415 patients (age 63 ± 11 years) are shown in Table 1.
Relationship between biomarkers and prevalent CAD
Compared with patients with angiographically normal (smooth) coronary arteries, those with
angiographic atherosclerosis had higher levels of HSP70, but FDP and CRP levels were not
significantly different. FDP and HSP70, but not CRP levels, were significantly lower in
patients with nonsignificant versus significant CAD (Online Table 1A). In univariate
analysis, the Gensini CAD severity score was significantly higher in patients with elevated
HSP70 and FDP levels (above their respective cutpoints), but not in those with an elevated
CRP level (Online Tables 1B and 1C). However, none of these differences remained
significant after multivariate adjustment with the aforementioned covariates (Online Table
2).
Clinical and demographic predictors of adverse outcomes
Over a median follow-up of 2.3 years, 283 patients died (8.3%) (150 were cardiac deaths
[4.9%] and 122 had an MI [3.6%]), and 371 had revascularization (10.8%) (Table 1). Using
Cox proportional hazard models that included all the aforementioned covariates, age (HR:
1.02, p = 0.004), diabetes (HR: 1.65, p < 0.0001), ever smoking (HR: 1.38, p = 0.0046),
Gensini score (HR: 1.003, p = 0.006), aspirin use (HR: 0.62, p = 0.001), clopidogrel use
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(HR: 1.51, p = 0.0008), acute MI at presentation (HR: 1.69, p <0.0001), eGFR (HR: 0.99, p
< 0.0001), and LVEF (HR: 0.98, p < 0.0001) were all independent predictors of the
combined outcomes of all-cause death and MI.
Relationships between individual biomarkers and outcomes
Cox proportional hazard regression models, adjusted for aforementioned covariates,
performed for individual biomarkers (natural log transformed) demonstrated that HSP70
(HR: 1.14, p < 0.0001) and CRP (HR: 1.29, p < 0.0001), but not FDP (p = 0.90), were
significantly associated with combined outcomes of death and MI. However, elevated levels
(above cutpoints) of HSP70, FDP, and CRP were each associated with increased risk of all-
cause death, cardiac deaths, the combined endpoint of cardiac or all-cause death and MI, and
the combined endpoint of death, MI, and revascularization (Table 2). All 3 biomarkers
predicted adverse CVD events in subgroups with nonsignificant CAD (<50% stenosis, n =
1,480) and in those with significant CAD (≥50% stenosis, n = 1,935) (Table 2).
Relationship between aggregate biomarker score and outcomes
There were significant but weak correlations between CRP and both HSP70 and FDP, and
between HSP70 and FDP (Online Table 1B). For each patient, a score of 0 or 1 was assigned
based on the presence or absence of elevated levels (above each cutpoint value) of each of
the 3 biomarkers, and an aggregate risk score between 0 and 3 was calculated. Compared
with those with 0 positive biomarkers (n = 1,248), patients with an elevated biomarker score
were more often black, had lower eGFRs and LVEFs, and had a greater frequency of
diabetes and smoking history (Table 1). Among the 4 groups stratified by biomarker
positivity, there were no significant differences between the management strategy (medical
management or revascularization) after index catheterization (Table 1).
In unadjusted analyses, an increasing biomarker score (0 to 3) was associated with increased
risk of all-cause death (p for trend <0.0001), cardiac deaths (p for trend < 0.0001), MI (p for
trend <0.0001), and revascularization (p for trend <0.0001) (Table 1). There was a stepwise
decline in survival free of death (log rank p < 0.0001), death and MI events (log rank p <
0.0001), and the combined endpoint of death, MI, and revascularization (log rank p <
0.0001) with increasing biomarker risk score (Fig. 1).
The Cox proportional hazard regression model adjusting for all the previously described
covariates revealed that for each 1 point increase in risk score, the HR increased 1.87 (p
<0.0001) for all-cause death, 1.79 (p <0.0001) for cardiac death, 1.76 (p <0.0001) for
combined outcomes of death and MI, and 1.49 (p < 0.0001) for death, MI, and
revascularization. HRs of 1, 2, or 3 positive biomarkers compared with 0 are shown in Table
2 and Online Table 3, and the rates of annual CVD events in these aggregate risk score
categories are shown in Figure 2. The score was also associated with individual events of MI
(HR: 1.40, p = 0.0024) and revascularization (HR: 1.26, p = 0.0003) for each 1 point
increase in risk score.
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Discrimination testing
In the whole cohort and in the patients with nonsignificant and with significant CAD, the C
statistic increased significantly for prediction of cardiac deaths (referent C statistic = 0.76,
with added biomarker score, 0.80; p = 0.0002), all-cause death, for combined events of death
and MI, and for death, MI, and revascularization, when all 3 biomarkers were incorporated
into a model with the established risk factors both as a risk score or as categorical variables
(Table 3).
The NRI of the biomarker score for all-cause death and the combined events of death and
MI were 44% and 42%, respectively (Table 4). This corresponded to 14% and 13% rates of
correctly reclassifying events and 30% and 29% rates of correctly reclassifying nonevents,
respectively. The relative IDI for this model was 31% for deaths and 30% for death and MI.
There was improvement in both subgroups with and without significant CAD, with a trend
to greater NRI in those without significant CAD.
Subgroup analyses
Results were similar in the subgroups with either significant or nonsignificant CAD,
including those with normal coronary arteries (Table 2). A score of 3 corresponded to an
18%/year risk of death and MI in the significant CAD group and a 14%/year risk in the
nonsignificant CAD group (Fig. 2). Even after excluding patients with angiographically
normal smooth coronary arteries and those with acute MI on presentation, our results
remained unchanged.
We examined whether there was heterogeneity in the HRs based on age, sex, race, and
presence of individual risk factors, presentation with acute MI, severity of CAD, and eGFR
values. We found that aside from age (p = 0.003), eGFR (p = 0.03), and a diagnosis of
hypertension (p = 0.009), there was no significant interaction (p > 0.05) among these factors
and the predictive capacity of the risk score (Fig. 3).
Discussion
Multiple pathways contribute to the development of atherosclerotic plaque instability and
thereby increase the likelihood that plaques will rupture or erode. We identified 3 circulating
biomarkers (CRP, FDP, and HSP70) that are involved in signaling pathways that likely
influence plaque instability (including inflammation, coagulation, and stress-induced
cellular responses) and examined the hypothesis that each biomarker would predict risk, but
the more biomarkers that were abnormal, the greater the expected risk. Our results support
the validity of our underlying hypothesis. Among patients who underwent coronary
angiography for suspected or established CAD, these 3 biomarkers were significant and
independent predictors of risk of all-cause death, cardiac death, combined outcomes of death
and MI, and death, MI, and revascularization. Importantly, an aggregate score based on the
number of biomarkers that were abnormal was a more powerful predictor of higher risk. In
comparison to patients with a 0 biomarker score, those who had a risk score of 3 (<5% of the
population) experienced over a 5-fold increased risk of all-cause death or MI within 1 year,
with an annual rate of more than 16%. The aggregate risk score significantly improved
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discrimination of future death and MI risk over a standard clinical model, as evidenced by
improvement in the C statistic and NRI.
Current evidence suggests that signaling pathways and their effector molecules involved in
the development of plaque rupture are different from pathways involved in atherogenesis.
Thus, a biomarker that is a predictor of adverse events emanating from the development of
CAD in a population that is initially free of existing CAD is not necessarily a predictor of
events in patients with established, or likely, CAD.
C-reactive protein
Many population-based studies in subjects free of known CAD have found that CRP adds to
risk prediction above standard risk factor assessment (23,24). However, results remain
unclear in patients with CAD. In a meta-analysis of 83 studies in patients with CAD, an
elevated CRP posed an adjusted relative risk of only 1.19 (25). In our high-risk population,
an elevated CRP level increased risk by a higher, but still modest, 1.6-fold.
Heat shock protein 70
Heat shock or stress proteins are highly conserved molecules that fulfill a range of functions,
including cytoprotection and the intracellular assembly, stabilization, folding, and
translocation of oligomeric proteins. Their synthesis can be induced by a range of cellular
insults, including oxidative, hemodynamic, and inflammatory stress, all of which are
associated with the development of CAD (11–13). The relation between cardiovascular
outcomes and circulating HSP70 levels is controversial. In cross-sectional studies, elevated
levels of HSP70 were associated with a lower prevalence of CAD and of carotid intimal
thickness (26,27). These differences are most likely due to the fact that previous studies
investigated risk of atherogenesis, whereas our present investigation focuses on whether the
biomarkers are predictive of subsequent plaque rupture. HSP70 levels increase after an acute
MI, indicating that acute MI can cause an increase in HSP70 (28,29). In our study, 12% of
patients presented with an acute MI; however, our findings did not change after exclusion of
this subset.
Fibrin degradation products
We employed FDP, and not D-dimer, to assess coagulation products. The immunoassay was
designed to detect the full complement of fibrin and FDP (fibrin mono- and oligomers,
fragments -X, -Y, and -E), providing an increased ability to measure coagulation-related
products. Moreover, we found that FDP was not a predictor of adverse events when used as
a continuous variable, but was an independent predictor using the cutoff value. This suggests
that there is threshold value for FDP (>75th percentile of the population mean) above which
it is associated with increased risk, and not with a continuous additive risk with increasing
values.
Previous studies have only examined the value of D-dimer levels with respect to long-term
outcomes. In population-based studies, D-dimer levels predicted adverse cardiovascular
events, but was not always independent of CRP (16,30). Importantly, in the BARI 2D
(Bypass Angioplasty Revascularization Investigation 2 Diabetes) study, the diabetics with
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CAD had higher D-dimer levels that were associated with an increased risk of cardiac events
(31).
Use of multiple biomarkers
Previous studies examining the role of multiple biomarkers in populations free of
established CAD have demonstrated only slight improvement in predictive capacity (using C
statistic) when added to standard clinical models (6–8). In contrast, our study establishes the
value of a multimarker aggregate score in a population with suspected or established CAD, a
group in which conventional risk scores such as the Framingham Risk Score have failed to
identify risk of recurrent cardiac events.
The measured biomarkers were not associated with either the presence or severity of CAD
after adjustment for risk factors, again emphasizing the concept that a biomarker that reflects
plaque instability is not necessarily useful for identifying presence or severity of coronary
plaque. There was minimal heterogeneity in the value of the biomarker risk score based on
clinical variables, risk factors, medication use, and LVEF. Patients presenting with acute MI,
which constituted 12% of our cohort, also had similar risk prediction compared with those
without MI at presentation, and exclusion of these patients did not significantly alter risk
prediction. Approximately two-thirds of our CAD patients underwent revascularization, and
the remaining were treated with medical therapy upon discharge after cardiac
catheterization; however, the rate of revascularization was similar between the various
biomarker risk score groups. Including the revascularization strategy in the Cox regression
model did not alter the overall HRs for the biomarker risk score.
Clinical cardiac events that include death, MI, and revascularization potentially result from
complex kinetic interactions between the magnitude of vascular stenoses and factors that
characterize plaque instability (32). The stenotic severity, reflected by the Gensini score,
drives symptoms and some revascularization procedures, whereas plaque instability leads to
death and MI events. Our results are in agreement with this concept because the Gensini
score and the biomarkers were all independent predictors of outcome.
Study strengths
We enrolled consecutive individuals, including women (35% of total cohort), blacks, those
with acute MI, and patients with a range of LVEFs, reflecting a population that is typical of
those undergoing cardiac catheterization. This is different from many biomarker studies that
are conducted retrospectively on highly select populations enrolled in clinical trials. Assays
were performed at 2 time points by the same laboratory personnel, which minimized
variability. C statistics, NRI, and IDI were calculated using survival models that allowed for
better model discrimination and overall predictive ability.
Study limitations
Limitations of our study include a 1-time measurement of biomarkers that may not reflect
levels at future time points. We have not studied other biomarkers, such as myeloperoxidase,
or myocardial specific markers, such as troponin and brain natriuretic peptide. Our results
need to be further validated and should not be extrapolated to the general population without
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suspected or known CAD. Whether more aggressive management in patients with an
elevated biomarker risk score will modify the score, and whether that will reflect lower risk
remains unknown and needs further investigation.
Although we characterized these biomarkers as representatives of specific biologic
pathways, signaling molecules are often involved in multiple pathways that interact with
each other. For example, HSP70 pathways independent of cellular stress may also contribute
to its biological actions (11–13,33). Our intent, therefore, was to use these 3 biomarkers as
probable reflectors of activation of multiple pathways commonly associated with vulnerable
plaque.
Conclusions
We have demonstrated that a strategy using an aggregate risk score consisting of 3
biomarkers (individually involved in inflammation, coagulation, and stress-induced cellular
responses) identifies patients with suspected or with established CAD who are at increased
risk of experiencing death and other adverse cardiac outcomes in the near and medium term.
Whether treatment aimed at reducing activity of these pathways can positively alter the
disease course remains to be determined and could be addressed in an adequately powered
randomized interventional trial based on biomarker evaluation.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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CABG coronary artery bypass grafting
CAD coronary artery disease
CRP C-reactive protein
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HSP70 heat shock protein 70
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IDI integrated discrimination improvement
LVEF left ventricular ejection fraction
MI myocardial infarction
NRI net reclassification improvement
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Figure 1. Kaplan-Meier Survival
Survival curves for biomarker risk score for (A) death and (B) death and myocardial
infarction (MI). Number of positive biomarkers are listed adjacent to each survival curve.
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Figure 2. Annual Rate of Death and MI
Rate of death and MI grouped by coronary artery disease (CAD) status and by biomarker
score. Percent of patients within each group listed in individual bars. Abbreviation as in
Figure 1.
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Figure 3. Forest Plot of Interaction With Cardiovascular Risk Factors for 1 Unit of Biomarker
Risk Score for Outcomes of Death and MI
AMI = acute myocardial infarction; eGFR = estimated glomerular filtration rate; LVEF =
left ventricular ejection fraction.
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Table 2
Hazard Ratios for All-Cause Death, Combined Endpoints of Death and MI, and Combined Endpoints of
Death, MI, and Revascularization According to Biomarker Levels
Variables
All Participants
HR (95% CI); p Value
Significant CAD
HR (95% CI); p Value
Nonsignificant
CAD HR (95% CI); p Value
All-Cause Death
 All biomarkers in same model
  CRP ≥3.0 mg/l 1.80 (1.36–2.38); <0.0001 1.60 (1.13–2.27); 0.0087 2.36 (1.46–3.81); 0.0005
  HSP70 at ≥0.625 ng/ml 2.02 (1.51–2.70); <0.0001 1.86 (1.28–2.70); 0.0012 2.29 (1.42–3.69); 0.0007
  FDP ≥1.0 μg/ml 1.91 (1.46–2.49); <0.0001 1.60 (1.13–2.27); 0.0087 1.74 (1.11–2.71); 0.0152
 Continuous biomarker risk score 1.87 (1.63–2.15); <0.0001 1.74 (1.45–2.08); <0.0001 2.07 (1.65–2.60); <0.0001
 Categorical biomarker risk score
  1 vs. 0 markers 1.70 (1.16–2.50); 0.0065 1.76 (1.09–2.84); 0.0198 1.62 (0.84–3.13); 0.1520
  2 vs. 0 markers 3.69 (2.52–5.41); <0.0001 3.26 (2.01–5.27); <0.0001 4.58 (2.39–8.80); <0.0001
  3 vs. 0 markers 5.79 (3.63–9.22); <0.0001 4.89 (2.64–9.06); <0.0001 7.07 (3.33–15.03); <0.0001
Cardiac Death
 All biomarkers in same model
  CRP ≥3.0 mg/l 1.76 (1.19–2.60); 0.0049 1.59 (0.98–2.56); 0.0587 2.37 (1.17–4.81); 0.0164
  HSP70 ≥0.625 ng/ml 1.69 (1.13–2.53); 0.0102 1.46 (0.88–2.41); 0.1436 2.17 (1.07–4.40); 0.0327
  FDP ≥1.0 μg/ml 2.00 (1.38–2.89); 0.0003 2.06 (1.29–3.27); 0.0023 1.69 (0.89–3.21); 0.1072
 Continuous biomarker risk score 1.79 (1.47–2.17); <0.0001 1.68 (1.32–2.14); <0.0001 1.97 (1.41–2.75); <0.0001
 Categorical biomarker risk score
  1 vs. 0 markers 1.53 (0.90–2.58); 0.1155 1.54 (0.80–2.97); 0.1939 1.58 (0.64–3.90); 0.3255
  2 vs. 0 markers 3.02 (1.77–5.15); <0.0001 2.94 (1.52–5.66); 0.0013 3.18 (1.24–8.17); 0.0163
  3 vs. 0 markers 5.24 (2.79–9.86); <0.0001 4.26 (1.88–9.66); 0.0005 7.36 (2.56–21.17); 0.0002
All-Cause Death or MI
 All biomarkers in same model
  CRP ≥3.0 mg/l 1.61 (1.28–2.03); <0.0001 1.55 (1.17–2.06); 0.0023 1.93 (1.27–2.93); 0.0019
  HSP70 ≥0.625 ng/ml 2.26 (1.77–2.90); <0.0001 2.32 (1.70–3.15); <0.0001 2.18 (1.42–3.33); 0.0003
  FDP ≥1.0 μg/ml 1.62 (1.28–2.04); <0.0001 1.50 (1.12–2.00); 0.0067 1.77 (1.18–2.66); 0.0059
 Continuous biomarker risk score 1.76 (1.56–1.98); <0.0001 1.70 (1.46–1.97); <0.0001 1.92 (1.57–2.36); <0.0001
 Categorical biomarker risk score
  1 vs. 0 markers 1.83 (1.33–2.51); 0.0002 2.03 (1.38–2.99); 0.0003 1.50 (0.86–2.61); 0.15
  2 vs. 0 markers 3.46 (2.51–4.78); <0.0001 3.31 (2.22–4.92); <0.0001 3.93 (2.25–6.87); <0.0001
  3 vs. 0 markers 4.99 (3.31–7.53); <0.0001 4.80 (2.81–8.21); <0.0001 5.62 (2.86–11.06); <0.0001
All-Cause Death, MI, or Revascularization
 All biomarkers in same model
  CRP ≥3.0 mg/l 1.26 (1.06–1.49); 0.0084 1.13 (0.93–1.38); 0.22 1.86 (1.32–2.60); 0.0003
  HSP70 ≥0.625 ng/ml 1.97 (1.64–2.36); <0.0001 2.01 (1.62–2.50); <0.0001 1.95 (1.37–2.78); 0.0002
  FDP ≥1.0 μg/ml 1.47 (1.22–1.76); <0.0001 1.32 (1.05–1.65); 0.0172 1.76 (1.26–2.46); 0.0010
 Continuous biomarker risk score 1.49 (1.36–1.63); <0.0001 1.39 (1.25–1.55); <0.0001 1.84 (1.55–2.18); <0.0001
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Variables
All Participants
HR (95% CI); p Value
Significant CAD
HR (95% CI); p Value
Nonsignificant
CAD HR (95% CI); p Value
 Categorical biomarker risk score
  1 vs. 0 markers 1.59 (1.29–1.97); <0.0001 1.60 (1.26–2.04); 0.0001 1.69 (1.10–2.59); 0.0177
  2 vs. 0 markers 2.44 (1.94–3.06); <0.0001 2.11 (1.62–2.75); <0.0001 3.68 (2.33–5.79); <0.0001
  3 vs. 0 markers 3.05 (2.19–4.23); <0.0001 2.48 (1.63–3.77); <0.0001 5.41 (3.04–9.63); <0.0001
Values are hazard ratios (HRs) and 95% confidence intervals (CI).
Abbreviations as in Table 1.
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Table 3
C-Statistic for Cox Regression Models Predicting Major Adverse Cardiovascular Events
Variables
All Participants
C Statistic; p Value
Significant CAD
C Statistic; p Value
Nonsignificant CAD
C statistic; p Value
All-cause death
 Established risk factors 0.722; referent 0.734; referent 0.755; referent
 Established risk factors + score 0.784; <0.0001 0.783; <0.0001 0.815; 0.001
All-cause death and MI
 Established risk factors 0.694; referent 0.703; referent 0.708; referent
 Established risk factors + score 0.750; <0.0001 0.744; <0.0001 0.773; 0.001
All-cause death, MI, and Revascularization
 Established risk factors 0.677; referent 0.653; referent 0.691; referent
 Established risk factors + score 0.707; <0.0001 0.671; 0.009 0.751; 0.0006
Abbreviations as in Table 1.
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Table 4
NRI and IDI for Death and MI Using Biomarker Score
Variables All Participants Significant CAD Nonsignificant CAD
Events correctly reclassified 13% 6% 16%
Nonevents correctly reclassified 29% 26% 29%
NRI 42% 33% 45%
IDI 0.03 0.03 0.03
IDI = integrated discrimination improvement; NRI = net reclassification improvement; other abbreviation as in Table 1.
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